Sponsored by Cagent Vascular

Introducing Serration Technology

By Peter A. Schneider, MD
 

We have had 40 years to perfect balloon angioplasty. Considering its simplicity and low cost, it is an incredible tool for dilatation. In many different procedures over multiple decades, balloon angioplasty has served as definitive therapy. As endovascular approaches and techniques have been applied to more complex lesion morphology, multiple, more advanced definitive therapies have been developed, including drug-coated balloons, drug-eluting stents, stent grafts, bare-metal stents, and woven nitinol stents. All these technologies depend, to some degree, on vessel dilatation. Clinical experience and data are accumulating that demonstrate a need for reliable lumen gain and arterial expansion as part of the endovascular armamentarium for dilatation of lesions.

Drug-coated balloons in particular present a conundrum. Drug uptake may depend on the angioplasty mechanism creating dissection. Aggressive percutaneous transluminal angioplasty with slight oversizing, full expansion, and inflation within 30 seconds of entering the bloodstream are all desirable to promote drug transfer and good results. At the same time, interventionists are attempting to limit dissection by careful balloon technique so that the arterial surface will be smooth.

This is where the value of obstructive lesion treatment with a product like the Serranator® (Cagent Vascular) could make a difference in ensuring optimum lumen gain. Serrations in particular may be a good way to dilate a vessel. By creating microchannels, the Serranator® provides a line along which the serration balloon energy will dissipate, creating more predictability and control of the lumen expansion. The concept of creating serrations is new to angioplasty; however, it is widely used across multiple industries.

I believe this new technology will offer the same simple, familiar, versatile, easy-to-use features we all know well of standard angioplasty.

Peter A. Schneider, MD
Chief of Vascular Surgery
Kaiser Foundation Hospital
Honolulu, Hawaii
peterschneidermd@aol.com
Disclosures: Chief Medical Officer for Cagent Vascular.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.